The estimated Net Worth of Steven C Gilman is at least $1.41 Milion dollars as of 4 September 2024. Steven Gilman owns over 5,000 units of Vericel Corp stock worth over $699,200 and over the last 10 years he sold VCEL stock worth over $495,231. In addition, he makes $220,085 as Independent Director at Vericel Corp.
Steven has made over 29 trades of the Vericel Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of VCEL stock worth $18,700 on 4 September 2024.
The largest trade he's ever made was buying 20,000 units of Vericel Corp stock on 27 July 2016 worth over $49,600. On average, Steven trades about 1,833 units every 34 days since 2015. As of 4 September 2024 he still owns at least 16,000 units of Vericel Corp stock.
You can see the complete history of Steven Gilman stock trades at the bottom of the page.
Dr. Steven C. Gilman, Ph.D., is an Independent Director of the company. Dr. Gilman is a director since January 2015, served as the Chairman of the board of directors and Chief Executive Officer of ContraFect Corporation until his retirement in April 2019. He previously served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals from September 2010 until its acquisition by Merck & Co., in January 2015. Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and Chief Executive Officer of ActivBiotics, Inc., a privately-held biopharmaceutical company, from March 2004 to October 2007. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles, including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development and has also held scientific, business, and academic appointments at Wyeth Pharmaceuticals, Inc., Cytogen Corporation, Temple Medical School, and Connecticut College. Dr. Gilman currently serves on the boards of directors of ContraFect Corporation, SCYNEXIS, Inc. and Akebia Therapeutics, Inc. and on the board of directors and compensation committee of Momenta Pharmaceuticals, Inc. Dr. Gilman has previously served on the boards of directors of the Massachusetts Biotechnology Association and Keryx Biopharmaceuticals, Inc., prior to its merger with Akebia Therapeutics. Dr. Gilman has also held advisory roles on the Penn State University biotechnology board and the Northeastern University drug discovery board. Dr. Gilman received his B.A. in microbiology from Miami University of Ohio and a Ph.D. and M.S. degree in microbiology from Pennsylvania State University. Dr. Gilman performed his post-doctoral training at Scripps Clinic and Research Foundation.
As the Independent Director of Vericel Corp, the total compensation of Steven Gilman at Vericel Corp is $220,085. There are 11 executives at Vericel Corp getting paid more, with Dominick Colangelo having the highest compensation of $5,385,530.
Steven Gilman is 67, he's been the Independent Director of Vericel Corp since 2017. There are 1 older and 13 younger executives at Vericel Corp. The oldest executive at Vericel Corp is Robert Zerbe, 69, who is the Independent Chairman of the Board.
Steven's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel a Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Vericel Corp executives and other stock owners filed with the SEC include: